Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas
A Phase I Trial Of 17-Allylaminogeldanamycin (17-AAG) And PS341 In Advanced Malignancies
Sponsor: National Cancer Institute (NCI)
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from National Cancer Institute (NCI)
Other AIDS-related Peripheral/Systemic Lymphoma trials with similar outcome
Listed as NCT00096005, this PHASE1 trial focuses on AIDS-related Peripheral/Systemic Lymphoma and Adult Grade III Lymphomatoid Granulomatosis and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 6 times since 2004, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Nov 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .